Literature DB >> 26902988

Interactions with industry under the Sunshine Act: an example from gynecologic oncology.

David I Shalowitz1, Monique A Spillman2, Mark A Morgan3.   

Abstract

THE PROBLEM: Clinicians may be unaware that industry payments to physicians are now publicly searchable under the Physician Payments Sunshine Act. Furthermore, the extent of industry's financial involvement in subspecialty practice has not been previously accessible. As an example, 6948 direct, research-unrelated payments totaling $1,957,004 were made to 765 gynecologic oncologists in 2014, the first full year of data available. A total of 153 companies reported at least 1 payment; however, the 10 manufacturers reporting the highest total payment amount accounted for 82% of all payments to physicians. In all, 48 gynecologic oncologists received >$10,000 from manufacturers, accounting for $1,202,228, or 61%, of total payments. A SOLUTION: Obstetrician-gynecologists, including gynecologic oncologists, should be aware of their publicly reported payments from industry and ensure reports' accuracy. Professional organizations, including the Society of Gynecologic Oncology (SGO), should strongly consider proactively developing guidelines regarding interactions with industry for their general memberships.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Sunshine Act; conflict of interest; ethics; gynecologic oncology

Mesh:

Year:  2016        PMID: 26902988     DOI: 10.1016/j.ajog.2016.02.035

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  The Sunshine Act and oncology: Lessons learned from urology.

Authors:  Mahir Maruf; Piyush K Agarwal; Abhinav Sidana
Journal:  Semin Oncol       Date:  2017-10-13       Impact factor: 4.929

2.  Association of Gender With Financial Relationships Between Industry and Academic Otolaryngologists.

Authors:  Jean Anderson Eloy; Michael Bobian; Peter F Svider; Ashley Culver; Bianca Siegel; Stacey T Gray; Soly Baredes; Sujana S Chandrasekhar; Adam J Folbe
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-08-01       Impact factor: 6.223

3.  The Invisible Hand of Industry.

Authors:  X Mona Guo; Emma L Barber
Journal:  Clin Obstet Gynecol       Date:  2022-02-28       Impact factor: 1.966

4.  Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions.

Authors:  Avinash R Patwardhan
Journal:  Inquiry       Date:  2016-09-16       Impact factor: 1.730

5.  Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.

Authors:  Susan F Wood; Joanna Podrasky; Meghan A McMonagle; Janani Raveendran; Tyler Bysshe; Alycia Hogenmiller; Adriane Fugh-Berman
Journal:  PLoS One       Date:  2017-10-25       Impact factor: 3.240

6.  Sociodemographic disparities in access to ovarian cancer treatment.

Authors:  Shannon Graham; Elaine Hallisey; Grete Wilt; Barry Flanagan; Juan L Rodriguez; Lucy Peipins
Journal:  Ann Cancer Epidemiol       Date:  2019-11-27

Review 7.  Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.

Authors:  Freek Fickweiler; Ward Fickweiler; Ewout Urbach
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.